A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Public ClinicalTrials.gov record NCT02634346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia
Study identification
- NCT ID
- NCT02634346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alkermes, Inc.
- Industry
- Enrollment
- 403 participants
Conditions and interventions
Conditions
Interventions
- ALK3831 Drug
- Olanzapine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2015
- Primary completion
- May 24, 2017
- Completion
- Jun 6, 2017
- Last update posted
- Jun 26, 2018
2015 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Little Rock | Arkansas | 72211 | — |
| Alkermes Investigational Site | Springdale | Arkansas | 72764 | — |
| Alkermes Investigational Site | Culver City | California | 90230 | — |
| Alkermes Investigational Site | Garden Grove | California | 92845 | — |
| Alkermes Investigational Site | Lemon Grove | California | 91945 | — |
| Alkermes Investigational Site | Long Beach | California | 90822 | — |
| Alkermes Investigational Site | Orange | California | 92868 | — |
| Alkermes Investigational Site | San Diego | California | 92103 | — |
| Alkermes Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Alkermes Investigational Site | North Miami | Florida | 33161 | — |
| Alkermes Investigational Site | Chicago | Illinois | 60640 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63141 | — |
| Alkermes Investigational Site | Las Vegas | Nevada | 89102 | — |
| Alkermes Investigational Site | Marlton | New Jersey | 08053 | — |
| Alkermes Investigational Site | Dayton | Ohio | 45417 | — |
| Alkermes Investigational Site | Dallas | Texas | 75243 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02634346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2018 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02634346 live on ClinicalTrials.gov.